Sema4 announces on January 9, 2023, it is changing its name to GeneDx and getting a new NASDAQ ticker as WGS (aka whole genome sequencing).
GemeDx was the longstanding name of the genetics lab division of Bioreference (itself part of OPKO). GeneDx was acquired by Sema4 in January 2022 for $623M per Fierce Biotech. Sema4 has had a difficult stock price ride, from $20 to 30 cents in about 24 months.
See open access story at Genomeweb.
